THE DEFINITIVE GUIDE TO AGO TUMOR

Hormonal therapy remains the therapy of very first choice for metastatic patients with endocrine-responsive breast cancer (LoE 1a A, AGO ++). The sequential use with the accessible prescription drugs depends on the person pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of prognosis of relapse is suggested Anytime doable,